Hopstem Biotechnology
- Biotech or pharma, therapeutic R&D
Hopstem aims to develop innovative iPSC cell therapy for global CNS patients. The potential RMAT, BIC and FIC hNPC01 injection received IND clearance from FDA and NMPA, completed Phase I study for chronic stroke in June 2025. Hear us @ Jun 17 11:45 153C.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}